Die Resektion solitärer Lungenmetastasen des Urothelkarzinom kann das Überleben bei selektionierten Patienten verlängern

Zusammenfassung

Die aktuelle Datenlage der pulmonalen Metastasektomie des Urothelkarzinoms ist stark begrenzt. In unserer aktuellen Studie haben wir basierend auf unserer 20-jährigen Zentrumserfahrung das Langzeitergebnis nach Lungenmetastasektomie bei Urothelkarzinom sowie die Faktoren, die ein Langzeitüberleben beeinflussen, untersucht. Bei insgesamt 18 Patienten (4 Frauen und 14 Männer) wurde eine Lungenmetastasektomie bei Urothelkarzinom in den Jahren von 2000 bis 2020 in kurativer Intention durchgeführt. Klinische, demografische und chirurgische Daten wurden retrospektiv analysiert. Das krankheitsfreie Intervall zwischen Behandlung des Primarius und Lungenmetastasektomie umfasste 1 bis 48 Monate. Die Überlebensanalyse wurde nach der Kaplan-Meier-Methode und dem Log-Rank-Test durchgeführt. Das kumulative 3- und 5-Jahres-Überleben betrug 84,7% und 52,9%. Die Resektion einer solitären Lungenmetastase war ein unabhängiger positiver Prädiktor für ein längerfristiges Überleben (p = 0,04). Die pulmonale Metastasektomie bei Urothelkarzinom ist mit einem günstigeren Langzeitergebnis verbunden und singuläre Metastasen mit einem verlängerten Langzeitüberleben. Die operative Resektion solitärer Lungenmetastasen und die Metastasektomie bei Rezidivmetastase des Urothelkarzinoms ist eine praktikable Therapie bei selektierten Patienten.

Abstract

There are only a few small published studies on pulmonary metastasectomy for urinary tract transitional cell carcinoma (TCC). In this study, we examined the long-term outcome and the prognostic survival factors associated with pulmonary metastasectomy of urinary tract TCC, as based on our centre’s 20-year experience. Between 2000 and 2020, curative pulmonary metastasectomy was performed in 18 patients (14 males and 4 females). Clinical, demographical and surgical data were retrospectively analysed. The disease-free interval between treatment of the primary tumour and pulmonary metastasectomy ranged from one to 48 months. Survival analysis was conducted with the Kaplan-Meier method and log-rank test. The 3- and 5-year survival rates were 84.7% and 52.9%, respectively. Resection of solitary metastases was a positive and independent factor for survival (p = 0.04). Pulmonary metastasectomy of urinary tract TCC is associated with a favourable outcome and solitary metastasis is associated with long-term survival. Surgical resection of solitary pulmonary metastasis and repeated lung metastasectomy by pulmonary recurrence from a urinary tract TCC is feasible in selected patients.

Schlüsselwörter

Metastase - Urothelkarzinom - Blasenkarzinom - Lungenmetastasektomie

Keywords

bladder cancer - metastases - urothelial carcinoma - pulmonary metastasectomy

Publication History

Received: 05 May 2022

Accepted after revision: 31 July 2023

Article published online:
05 September 2023

• Literatur

• 1 Siefker-Radtke AO, Walsh GL, Pisters LL. et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004; 171: 145-148 DOI: 10.1097/01.ju.0000099823.60465.e6. (PMID: 14665863)
• 2 Matsuguma H, Yoshino I, Ito H. et al. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?. Ann Thorac Surg 2011; 92: 449-453 DOI: 10.1016/j.athoracsur.2011.03.097. (PMID: 21801905)
• 3 Lehmann J, Suttmann H, Albers P. et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009; 55: 1293-1299 DOI: 10.1016/j.eururo.2008.11.039. (PMID: 19058907)
• 4 Han WS, Kim K, Park JS. Result of surgical resection for pulmonary metastasis from urothelial carcinoma. Korean J Thorac Cardiovasc Surg 2012; 45: 242-245 DOI: 10.5090/kjtcs.2012.45.4.242. (PMID: 22880169)
• 5 Kanzaki R, Higashiyama M, Fujiwara A. et al. Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact Cardiovasc Thorac Surg 2010; 11: 60-64
• 6 Abe T, Kitamura H, Obara W. et al. Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan. J Urol 2014; 191: 932-936 DOI: 10.1016/j.juro.2013.11.004. (PMID: 24211599)
• 7 Pfannschmidt J, Egerer G, Bischof M. et al. Surgical intervention for pulmonary metastases. Dtsch Arztebl Int 2012; 109: 645-651 DOI: 10.3238/arztebl.2012.0645. (PMID: 23094000)
• 8 Kim T, Ahn JH, Yo D. et al. Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. Clin Genitourin Cancer 2015; 13: e297-e304 DOI: 10.1016/j.clgc.2015.04.013. (PMID: 26007709)
• 9 Orteza AM, Kandzari SJ, Milam DF. Transitional cell carcinoma of the bladder with pulmonary metastasis: case report on 5-year survival following resection of metastasis. J Urol 1971; 105: 232-235 DOI: 10.1016/s0022-5347(17)61500-3. (PMID: 5090369)
• 10 Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology 1982; 20: 390-392 DOI: 10.1016/0090-4295(82)90462-9. (PMID: 7147508)
• 11 Oguzhan S, Sponholz S, Schirren M. et al. Metastases of Urothelium Carcinoma: Differential Diagnosis, Resection, and Survival. Thorac Cardiovasc Surg 2021; 6: 672-678 DOI: 10.1055/s-0041-1727150. (PMID: 33862636)
• 12 Luzzi L, Marulli G, Solli P. et al. Long-Term Results and Prognostic Factors of Pulmonary Metastasectomy in Patients with Metastatic Transitional Cell Carcinoma. Thorac Cardiovasc Surg 2017; 65: 567-571 DOI: 10.1055/s-0036-1583271. (PMID: 27148929)
• 13 Muilwijk T, Akand M, Van der Aa F. et al. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol 2020; 9: 1296-1305 DOI: 10.21037/tau-19-624. (PMID: 32676413)
• 14 Oosterlinck W, Lobel B, Jakse G. et al. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112 DOI: 10.1016/s0302-2838(01)00026-4. (PMID: 12074395)
• 15 Stenzl A, Cowan NC, De Santis M. et al. The updated EAU guidelines on muscleinvasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-825 DOI: 10.1016/j.eururo.2009.01.002. (PMID: 19157687)
• 16 Pfannschmidt J, Hoffmann H, Muley T. et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002; 74: 1653-1657 DOI: 10.1016/s0003-4975(02)03803-1. (PMID: 12440625)
• 17 Meimarakis G, Angele M, Staehler M. et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 2011; 202: 158-167 DOI: 10.1016/j.amjsurg.2010.06.029. (PMID: 21810496)
• 18 Kanzaki R, Higashiyama M, Fujiwara A. et al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg 2011; 39: 167-172 DOI: 10.1016/j.ejcts.2010.05.021. (PMID: 20591686)
• 19 Hofmann HS, Neef H, Krohe K. et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005; 48: 77-81 DOI: 10.1016/j.eururo.2005.03.004. (PMID: 15967255)
• 20 Murthy SC, Kim K, Rice TW. et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?. Ann Thorac Surg 2005; 79: 996-1003 DOI: 10.1016/j.athoracsur.2004.08.034. (PMID: 15734422)
• 21 Piltz S, Meimarakis G, Wichmann MW. et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002; 73: 1082-1087 DOI: 10.1016/s0003-4975(01)03602-5. (PMID: 11996245)